Skip to main content
. Author manuscript; available in PMC: 2019 Apr 1.
Published in final edited form as: Int J Dev Neurosci. 2017 Oct 27;65:66–82. doi: 10.1016/j.ijdevneu.2017.10.009

Figure 2.

Figure 2

Median (± Interquartile Range) eye opening scores collapsed across P13 – P16 for HIV-1 proteins (A) Tat dose treatment and (B) gp120dose treatment. No significant treatment effects were noted for either the gp120- or Tat treatments.